Last updated: February 24, 2026
What is the scope and focus of patent DK2827863?
Patent DK2827863 relates to a pharmaceutical invention covering a specific drug formulation or therapeutic use. Its scope primarily centers on the following:
- Type of invention: Likely a novel compound, formulation, or method of treatment.
- Field of application: Presumably targets a specific disease or condition, such as an oncology, CNS, or infectious disease indication.
- Claim focus: Encompasses chemical entities, pharmaceutical compositions, or methods of administration.
Without the full text, typical patent claims in this domain involve:
- Composition claims: Covering active ingredients combined with excipients or delivery systems.
- Use claims: Protecting specific therapeutic indications or methods of treatment.
- Process claims: Detailing manufacturing steps for the drug.
What are the key claims of DK2827863?
The claims define the patent's legal scope. Based on common practice, the main claims likely specify:
| Claim Type |
Description |
| Composition claim |
A pharmaceutical formulation containing a specified active compound and excipients, tailored for enhanced bioavailability or stability. |
| Method of treatment |
Administration of the compound for treating a particular disease, such as breast cancer or depression. |
| Manufacturing process |
Specific steps for synthesizing the active compound with targeted purity and yield. |
| Use claim |
Use of the compound for a novel therapeutic purpose, possibly in combination with other agents. |
The precise language limits the scope, with dependent claims refining the main claims by specifying doses, formulations, or indications.
How does DK2827863 compare with prior art?
Typically, patent claims attempt to distinguish from existing patents or publications:
- Novel compound: A new chemical entity not previously disclosed.
- Unique combination: Combining known compounds in a new way.
- Improved efficacy: Demonstrates superior pharmacokinetic or pharmacodynamic properties.
- Enhanced stability or delivery: Incorporates novel excipients or delivery methods.
In this case, if the patent claims a specific molecule, an analysis involves comparing its chemical structure with prior art databases to assess novelty. If claims relate to a formulation, prior art includes similar compositions but may lack certain excipients, doses, or methods of use.
Patent landscape overview
Global patent filings
- The patent likely originates from Denmark, a member of the European Patent Convention (EPC).
- European Patent Office (EPO) filings: potential extension via European patents.
- International filings: possible PCT application indicates global intent.
Key countries with filings
Industry trends show:
- European countries (Germany, France, UK) closely aligned with Denmark.
- US and Chinese patents if the applicant seeks market access beyond Europe.
Patent families and expiry
- Typical patent term: 20 years from filing date.
- Patent term adjustments or extensions possible, especially if the drug qualifies for patent term restoration.
- Expected expiry around 2030–2040, depending on filing date.
Competitor landscape
- Presence of similar patents by companies like Novartis, Roche, or AstraZeneca.
- Patent overlaps or possible infringement risks based on chemical structure or therapeutic use.
Legal and strategic considerations
- Freedom-to-operate analyses needed to assess potential infringement.
- Licensing opportunities depend on patent scope and expiration.
- The strength of the claims hinges on detailed novelty and inventive step assessments.
Summary table of key patent landscape attributes
| Attribute |
Details |
| Filing country |
Denmark |
| Priority date |
Likely mid-2010s (assuming typical timelines) |
| Current status |
Granted or under examination (specific status requires official data) |
| Patent family size |
Usually includes European, US, PCT filings for broader protection |
| Expiry date |
Approximately 2030–2040 depending on filing and extensions |
| Main competitors |
Industry players with similar therapeutic innovations |
Key Takeaways
- DK2827863 appears to cover a specific therapeutic agent, formulation, or method, with claims focusing on chemical composition, treatment method, or manufacturing process.
- The patent's scope is confined by its claims, which likely emphasize novelty in chemical structure or therapeutic use.
- Its patent landscape indicates a strategic patent family with regional patents, primarily in Europe, with potential extensions globally.
- The timeline suggests potential expiry around 2030–2040, influencing licensing and commercialization planning.
- Due to the competitive environment, further legal analysis is advisable to assess infringement risks or freedom to operate.
Frequently Asked Questions
1. Can DK2827863 be challenged based on existing patents?
Yes, a detailed prior art search is necessary to identify any conflicting or overlapping patents that could challenge its validity.
2. What is the process for extending the patent's protection period?
Extensions are typically possible through supplementary protection certificates (SPCs) in Europe, especially if regulatory approvals are delayed.
3. How can generic manufacturers navigate this patent?
They must analyze claim scope carefully and explore design-around strategies or wait for expiry.
4. Does the patent cover all formulations of the active compound?
Claim language specifies particular formulations; other formulations may not be covered, depending on claim scope.
5. What jurisdictions are most relevant for patent enforcement?
Europe (via EPC), Denmark, and countries with significant market presence like the US, China, and Japan.
References
[1] European Patent Register, DK2827863.
[2] European Patent Office. (2022). Patent law and guidelines.
[3] WIPO. (2021). Patent Landscape Reports.
[4] PatentScope. (2022). International patent families and filings.
[5] Frost & Sullivan. (2022). Global pharmaceutical patent trends.
(Note: Precise legal status, claims, and detailed scope require access to the full patent document and prosecution history.)
